LT3103456T - Dializės skysčio kompozicija, apimanti kristalizacijos inhibitorių medžiagas - Google Patents

Dializės skysčio kompozicija, apimanti kristalizacijos inhibitorių medžiagas

Info

Publication number
LT3103456T
LT3103456T LTEP16172654.2T LT16172654T LT3103456T LT 3103456 T LT3103456 T LT 3103456T LT 16172654 T LT16172654 T LT 16172654T LT 3103456 T LT3103456 T LT 3103456T
Authority
LT
Lithuania
Prior art keywords
composition
dialysis liquid
inhibitor substances
crystallisation inhibitor
crystallisation
Prior art date
Application number
LTEP16172654.2T
Other languages
English (en)
Inventor
Félix GRASES FREIXEDAS
Joan Perello Bestard
Fernando Tur Espinosa
Antonia Costa Bauza
Rafael M. Prieto Almirall
Isabel GOMILA MUÑIZ
Original Assignee
Universitat De Les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat De Les Illes Balears filed Critical Universitat De Les Illes Balears
Publication of LT3103456T publication Critical patent/LT3103456T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
LTEP16172654.2T 2008-08-06 2009-05-14 Dializės skysčio kompozicija, apimanti kristalizacijos inhibitorių medžiagas LT3103456T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200802363A ES2332636B1 (es) 2008-08-06 2008-08-06 Composicion de liquido de dialisis.

Publications (1)

Publication Number Publication Date
LT3103456T true LT3103456T (lt) 2020-05-11

Family

ID=41058532

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP16172654.2T LT3103456T (lt) 2008-08-06 2009-05-14 Dializės skysčio kompozicija, apimanti kristalizacijos inhibitorių medžiagas
LTEP09784119.1T LT2324835T (lt) 2008-08-06 2009-05-14 Dializės skysčio kompozicija, apimanti kristalizacijos inhibitorių medžiagas

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP09784119.1T LT2324835T (lt) 2008-08-06 2009-05-14 Dializės skysčio kompozicija, apimanti kristalizacijos inhibitorių medžiagas

Country Status (20)

Country Link
US (4) US8778912B2 (lt)
EP (2) EP3103456B1 (lt)
JP (4) JP2011529759A (lt)
CN (2) CN104224809A (lt)
AU (1) AU2009281096B2 (lt)
BR (1) BRPI0911938A2 (lt)
CA (2) CA2975801C (lt)
CY (2) CY1118089T1 (lt)
DK (2) DK3103456T3 (lt)
ES (3) ES2332636B1 (lt)
HK (1) HK1203843A1 (lt)
HR (2) HRP20161170T1 (lt)
HU (2) HUE049269T2 (lt)
LT (2) LT3103456T (lt)
MX (1) MX2011001278A (lt)
PL (2) PL2324835T3 (lt)
PT (2) PT2324835T (lt)
RU (2) RU2535094C2 (lt)
SI (2) SI2324835T1 (lt)
WO (1) WO2010018278A2 (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9364490B2 (en) * 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
DE102014013885A1 (de) 2014-09-18 2016-03-24 Fresenius Medical Care Deutschland Gmbh Dialyselösung
IL256064B2 (en) * 2015-06-04 2024-04-01 Amorphical Ltd Preparations of amorphous calcium carbonate for administration by inhalation, under the tongue or through the palate
DE102015007842A1 (de) * 2015-06-18 2016-12-22 Fresenius Medical Care Deutschland Gmbh Dialyselösung
US11707470B2 (en) 2015-12-11 2023-07-25 Eth Zurich Inositol derivatives for use in pathological crystallization
US11028112B2 (en) 2015-12-11 2021-06-08 Eth Zurich Inositol derivatives for use in pathological crystallization
EP3848053A1 (en) * 2015-12-11 2021-07-14 Universität Bern Inositol derivatives for use in pathological crystallization
CN107550992B (zh) * 2017-08-16 2018-05-25 安徽天康(集团)股份有限公司 一种治疗痛风的药物及其制备方法
CN112839661A (zh) 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
CA3130735A1 (en) 2019-01-30 2020-08-06 Sanifit Therapeutics, S.A. Inositol phosphate compounds for use in increasing tissular perfusion
US20220226356A1 (en) * 2019-05-10 2022-07-21 Fresenius Medical Care Deutschland Gmbh Composition and Concentrate for Use in Preparation of Dialysis Solution, Corresponding Dialysis Solution and Combinations Comprising Container
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
DE69333527T2 (de) * 1993-02-23 2005-06-16 Brigham & Women's Hospital, Inc., Boston Calciumrezeptoraktive moleküle
JPH1149671A (ja) * 1997-08-06 1999-02-23 Baxter Internatl Inc 腹膜透析液
RU2126973C1 (ru) * 1997-10-07 1999-02-27 Слюсарь Николай Николаевич Способ коррекции нарушений фосфоинозитидного обмена
EG24303A (en) * 1998-10-20 2009-01-12 Advanced Renal Technologies Buffered compositions for dialysis
DE19912850B4 (de) * 1999-03-22 2005-04-07 Fresenius Medical Care Deutschland Gmbh Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung
DE29910454U1 (de) * 1999-06-10 1999-09-23 Vitasyn GmbH, 10789 Berlin Mittel zur Therapie von Hyperphosphatämie
EP1223985B1 (en) * 1999-10-15 2005-11-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
JP2002249433A (ja) * 2000-12-19 2002-09-06 Sumitomo Pharmaceut Co Ltd 血管石灰化抑制剤
JP2003238414A (ja) * 2001-12-13 2003-08-27 Sangaku Renkei Kiko Kyushu:Kk 医薬組成物
AU2004287440A1 (en) * 2003-10-28 2005-05-19 Emory University Dialysates and methods and systems related thereto
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
ES2288126B2 (es) * 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.

Also Published As

Publication number Publication date
CY1118089T1 (el) 2017-06-28
PT2324835T (pt) 2016-10-25
CA2975801C (en) 2018-08-07
JP2016183196A (ja) 2016-10-20
RU2535094C2 (ru) 2014-12-10
HRP20161170T1 (hr) 2016-11-04
EP3103456A1 (en) 2016-12-14
AU2009281096B2 (en) 2016-07-21
PL2324835T3 (pl) 2017-01-31
JP2014210782A (ja) 2014-11-13
DK3103456T3 (da) 2020-05-04
HUE031173T2 (en) 2017-07-28
EP3103456B1 (en) 2020-02-12
HUE049269T2 (hu) 2020-09-28
CN104224809A (zh) 2014-12-24
JP2019019134A (ja) 2019-02-07
SI3103456T1 (sl) 2020-09-30
HRP20200733T1 (hr) 2020-10-16
CA2975801A1 (en) 2010-02-18
ES2332636B1 (es) 2011-02-10
WO2010018278A3 (es) 2010-12-16
LT2324835T (lt) 2016-10-10
ES2595227T3 (es) 2016-12-28
AU2009281096A1 (en) 2010-02-18
US20110172194A1 (en) 2011-07-14
MX2011001278A (es) 2011-05-30
WO2010018278A2 (es) 2010-02-18
US8778912B2 (en) 2014-07-15
CN102143754A (zh) 2011-08-03
JP6412068B2 (ja) 2018-10-24
CA2732881C (en) 2017-09-26
CA2732881A1 (en) 2010-02-18
PT3103456T (pt) 2020-05-06
US20170119799A1 (en) 2017-05-04
JP5978251B2 (ja) 2016-08-24
ES2785566T3 (es) 2020-10-07
RU2014127746A (ru) 2016-01-27
RU2691060C2 (ru) 2019-06-10
EP2324835A2 (en) 2011-05-25
RU2011115356A (ru) 2012-10-27
HK1203843A1 (en) 2015-11-06
JP6799041B2 (ja) 2020-12-09
PL3103456T3 (pl) 2020-09-21
BRPI0911938A2 (pt) 2015-10-20
CY1122973T1 (el) 2021-10-29
US20150374752A1 (en) 2015-12-31
US20140302166A1 (en) 2014-10-09
EP2324835B1 (en) 2016-07-20
DK2324835T3 (en) 2016-11-14
US9155750B2 (en) 2015-10-13
ES2332636A1 (es) 2010-02-09
JP2011529759A (ja) 2011-12-15
SI2324835T1 (sl) 2017-01-31

Similar Documents

Publication Publication Date Title
PL3103456T3 (pl) Kompozycja płynu dializacyjnego zawierająca substancje hamujące krystalizację
HK1223272A1 (zh) 程序性壞死的小分子抑制劑
PL3110901T3 (pl) Zastosowanie r-1233 w cieczowych urządzeniach chłodzących
HK1153222A1 (en) Liquid crystal compositions comprising mesogen containing compounds
ZA201006386B (en) Preparation of desulphurisation materials
BRPI0910515A2 (pt) composição líquida
PL2096090T3 (pl) Zastosowanie reaktywnego ciekłego spoiwa ceramicznego
PL1975226T3 (pl) Płynna kompozycja do obróbki
GB0807474D0 (en) Determination of Composition of Liquids
HK1154801A1 (en) Liquid composition comprising cisplatin-coordinating compound
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
EP2291654A4 (en) PREPARATION AND COMPOSITION OF INTER ALPHA INHIBITOR PROTEINS FROM BLOOD
IL208403A0 (en) Compositions and use of epas1 inhibitors
EP2285943A4 (en) LIQUID CLEANING COMPOSITIONS
GB0813840D0 (en) Improved liquid crystal compounds
PL2076243T3 (pl) Płynna formulacja G-CSF
EP2300354A4 (en) DISTRIBUTION OF FLUIDS
IL211688A (en) Crystalline form ii of calcium 3-acetylaminopropane-1-sulfonate
GB0819920D0 (en) Preparation of liquid concentrate milk-substitute
GB0819917D0 (en) Preparation of liquid concentrate milk-substitute
GB0803417D0 (en) Preparation of liquid concentrate milk-substitute
PL386910A1 (pl) Urządzenie do oczyszczania cieczy
FI20061022A0 (fi) Menetelmä nesteen annostelemiseksi
FI20060953A0 (fi) Menetelmä nesteen annostelemiseksi
GB0820150D0 (en) Method of mixinf=g fluids